Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Promises and challenges of personalized medicine to guide ARDS therapy CRITICAL CARE Wick, K. D., McAuley, D. F., Levitt, J. E., Beitler, J. R., Annane, D., Riviello, E. D., Calfee, C. S., Matthay, M. A. 2021; 25 (1): 404

Abstract

Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.

View details for DOI 10.1186/s13054-021-03822-z

View details for Web of Science ID 000721875300001

View details for PubMedID 34814925

View details for PubMedCentralID PMC8609268